Phase 3 trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+ mature T-cell lymphomas (MTCL).
Owen A. O'Connor
Consultant or Advisory Role - Seattle Genetics (U); Takeda (U)
Honoraria - Takeda
Research Funding - Seattle Genetics; Takeda
Barbara Pro
Consultant or Advisory Role - Seattle Genetics (U)
Research Funding - Seattle Genetics
Other Remuneration - Seattle Genetics
Tim Illidge
Consultant or Advisory Role - Seattle Genetics (U); Takeda (U)
Honoraria - Takeda
Research Funding - Seattle Genetics
Lorenz H. Trumper
Consultant or Advisory Role - Seattle Genetics (U)
Emily K. Larsen
Employment or Leadership Position - Seattle Genetics
Stock Ownership - Seattle Genetics
Dana A. Kennedy
Employment or Leadership Position - Seattle Genetics
Stock Ownership - Seattle Genetics